Serotonin Blockade Does Not Affect Nonarticular Tenderness in Healthy Volunteers

REFERENCES

• Pain, H Fields. McGraw-Hill, New York 1987
   Google Scholar
• Buskila D, Fefer P, Harman-Boehm I, Press J, Neumann L, Lunenfeld E, Gdalia A, Potashnik G, Sukenik S. Assessment of nonarticular tenderness and prevalence of fibromyalgia in huperprolactinemic women. J Rheumatol 1993; 20: 2112–2115
   PubMed Web of Science ®Google Scholar
• Houvenangel E, Forzy G, Leloire O. Cerebrospinal fluid monoamines in primary fibromyalgia. Rev Rheum Mal Osteartic 1990; 57: 21–23
   PubMedGoogle Scholar
• Russell I, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolism in fibromyalgia/fibrositis syndrome. Arthritis Rheum 1992; 35: 550–556
   PubMed Web of Science ®Google Scholar
• Taiwo Y, Levine J. Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 1992; 48: 485–490
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Skarphedinsson J, Delle M, Thoren P. Electrical stimulation of the gastrocnemius muscle in the spontaneously hypertensive rat increases the pain threshold: role of different serotonergic receptors. Acta Physiol Scand 1990; 138: 125–131
   PubMedGoogle Scholar
• Kishore Kumar R, Schafer S, Lawlor B, Murphy D, Max M. Single doses of the serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain. Pain 1989; 37: 223–227
   PubMedGoogle Scholar
• Johansson F, von Knorring L. A double-blind controlled study of serotonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients. Pain 1979; 7: 69–78
   PubMed Web of Science ®Google Scholar
• Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Kruger M, Schoeps P, Ackenheil M. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum. Nov; 1999; 42(11)2482–8
   Google Scholar
• Russel I J. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci. Jun; 1998; 315(6)377–84, Review
   Google Scholar
• Smythe H. Tender points: evolution of concepts of the fibrositis/fibromyalgia syndrome. Am J Med 1986; 81: 2–6
   PubMedGoogle Scholar
• Smythe H. Referred pain and tender points. Am J Med 1986; 81: 90–92
   PubMed Web of Science ®Google Scholar
• Moldofsky H, Warsh J. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (“fibrositis syndrome”). Pain 1978; 5: 65–71
   PubMed Web of Science ®Google Scholar
• Gruber A, Hudson J, Pope H. The management of treatment resistant depression in disorders on the inter face of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Psychiatr Clin North Am 1996; 19: 351–369
   PubMedGoogle Scholar
• Krag N, Norregaard J, Larsen J, Danneskiold-Samsoe B. A blinded, controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. Acta Psychiatrica Scandinavica 1994; 89: 370–375
   PubMed Web of Science ®Google Scholar
• Kravitz H, Katz R, Kot E, Helmke N, Fawcett J. Biochemical clues to a fibromyalgia-depression link: imipramine binding in patients with fibromyalgia or depression and in healthy controls. J Rheumatol 1992; 19: 1428–1432
   PubMed Web of Science ®Google Scholar
• Van Houdenhove B, Vasquez G, Neerinckx E. Tender points or tender patients?. The value of the psychiatric in-depth interview for assessing and understanding psychopathological aspects of fibromyalgia. Clin Rheumatol 1994; 13: 470–474
   PubMedGoogle Scholar
• Norregaard J, Bulow P, Prescott E, Jacobsen S. Preliminary results of a 4-year follow-up study in fibromyalgia. J Muscuoloske Pain 1993; 1(3/4)159–163
   Google Scholar
• Ledingham J, Doherty S, Doherty M. Primary fibromyalgia syndrome-an outcome study. Br J Rheumatol 1993; 32: 139–142
   PubMedGoogle Scholar
• Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975; 37: 341–351
   PubMed Web of Science ®Google Scholar
• Russell I, Michalek J, Vipraio G, Fletcher E, Javros M, Bowden C. Platelet-3H-imipramin up take receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1993; 19: 104–109
   Google Scholar
• Stratz T, Samborski W, Hrycaj P. Serum serotonin concentration in patients with generalized tendomyopathy (fibromyalgia) and rheumatoid arthritis. Med Klin 1993; 88: 458–462
   PubMedGoogle Scholar
• Platelet-³H-imipramin up take receptor density and serum serotonin levels inpatients with fibromyalgia/fibrositis syndrome (letter);, P Hrycaj, T Startz, W Muller
   Google Scholar
• Russel I J, Vipraio G A, Lopez Y. Reply. J Rheumatol 1993; 20(1)1986–1988
   PubMedGoogle Scholar
• Hamon M, Mallat M, Herbet A, Nelson D, Audinot M, Pichat L, Glowinski J. (3H)Metergoline: a new ligand of serotonin receptors in the rat brain. J Neurochem 1981; 36: 613–626
   PubMedGoogle Scholar
• Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res 1988; 8: 59–81
   PubMed Web of Science ®Google Scholar
• Structured Clinical Interview for DSM-III-R (SCID, version 1.0). 1 ed., R Spitzer, J Williams, M Gibbon, M First. American Psychiatric Press, Washington, DC 1990
   Google Scholar
• Mueller E A, Murphy D L, Sunderland T. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berl). 1986; 89(3)388–91
   PubMedGoogle Scholar
• Pigott T A, Zohar J, Hill J L, Bernstein S E, Grover G N, Zohar-Kadouch R C, Murphy D L. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. Mar 1; 1991; 9(5)418–26
   Google Scholar
• Lautenbacher S, Rollman G, McCain G. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain 1994; 59: 45–53
   PubMed Web of Science ®Google Scholar
• Wolfe F, Russell I J, Vipraio G, Ross KJ A. Serotonin levels, pain thresh old, and fibromyalgia symptoms in the general population. J Rheumatol 1997; 24: 555–559
   PubMed Web of Science ®Google Scholar
• Benkelfalt C, Murphy D, Zojar J, Hill J, Grover G, Insel T. Clomipramin in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism in action. Archives of General Psychiatry 1989; 46: 23–28
   PubMedGoogle Scholar
• Greenberg B, Benjamin J, Martin J, Keuler D, Huang S-J, Altemus M, Murphy D. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not un treated patients. Psychopharmacology (Berl). Dec; 1998; 140(4)434–44
   Google Scholar
• Ben-Zion I, Meiri G, Greenberg B, Murphy D, Benjamin J. Enhancement of CO2-induced anxiety in healthy volunteers with the serotonin antagonist metergoline. American Journal of Psychiatry 1999; 156: 1635–1637
   PubMedGoogle Scholar
• Pigott T A, Hill J L, Grady T A, L'Heureux F, Bernstein S, Rubenstein C S, Murphy D L. A comparison of the behavioral effects of oral versus intravenous mCPP ad ministration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry. Jan 1; 1993; 33(1)3–14
   Google Scholar